Innate Pharma S.A. (NASDAQ:IPHA – Get Rating) – Research analysts at SVB Leerink dropped their FY2022 EPS estimates for shares of Innate Pharma in a research report issued on Tuesday, November 15th. SVB Leerink analyst D. Graybosch now expects that the company will post earnings per share of ($0.47) for the year, down from their prior forecast of ($0.45). SVB Leerink has a “Outperform” rating and a $9.00 price target on the stock. The consensus estimate for Innate Pharma’s current full-year earnings is ($0.42) per share. SVB Leerink also issued estimates for Innate Pharma’s FY2023 earnings at ($0.70) EPS, FY2024 earnings at ($0.55) EPS, FY2025 earnings at ($0.78) EPS and FY2026 earnings at ($0.12) EPS.
Other equities research analysts have also issued reports about the stock. Kepler Capital Markets lowered shares of Innate Pharma from a “buy” rating to a “hold” rating and set a €3.10 ($3.20) target price on the stock. in a research report on Wednesday, August 3rd. Citigroup decreased their target price on shares of Innate Pharma from $16.00 to $12.00 and set a “buy” rating on the stock in a research report on Friday, September 16th.
Innate Pharma Trading Up 1.4 %
Institutional Investors Weigh In On Innate Pharma
Several institutional investors and hedge funds have recently made changes to their positions in IPHA. Balyasny Asset Management LLC acquired a new position in Innate Pharma in the 3rd quarter valued at about $32,000. Jane Street Group LLC raised its stake in Innate Pharma by 156.3% in the 1st quarter. Jane Street Group LLC now owns 37,736 shares of the company’s stock valued at $127,000 after purchasing an additional 23,012 shares during the last quarter. Optiver Holding B.V. raised its stake in Innate Pharma by 366.8% in the 2nd quarter. Optiver Holding B.V. now owns 181,944 shares of the company’s stock valued at $491,000 after purchasing an additional 142,970 shares during the last quarter. Finally, BlackRock Inc. raised its stake in Innate Pharma by 27.4% in the 1st quarter. BlackRock Inc. now owns 504,408 shares of the company’s stock valued at $1,695,000 after purchasing an additional 108,335 shares during the last quarter. 1.20% of the stock is currently owned by hedge funds and other institutional investors.
Innate Pharma Company Profile
Innate Pharma SA, a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; Avdoralimab (IPH5401), a monoclonal antibody blocking C5a binding to C5aR1 that is in Phase II clinicals trials for the treatment of COVID-19, bullous pemphigoid, chronic spontaneous urticaria, and other inflammatory diseases; IPH5201, a blocking antibody that is in Phase 1 clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; and IPH6101, a NKp46-based NK cell engager for the generation and evaluation of up to two bispecific NK cell engagers.
- Get a free copy of the StockNews.com research report on Innate Pharma (IPHA)
- MarketBeat: Week in Review 11/14 – 11/18
- Target’s Double Bottom Might Have Just Been Confirmed
- How High Can the Fed Go? How to Trade it
- Verra Mobility Stock Has Returned Back to the Station
- Does ASML’s November Rally Have Staying Power?
Receive News & Ratings for Innate Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innate Pharma and related companies with MarketBeat.com's FREE daily email newsletter.